Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications
Abstract Ipatasertib, an AKT inhibitor, in combination with prednisone and abiraterone, is under evaluation for the treatment of metastatic castration‐resistant prostate cancer (mCRPC). Hyperglycemia is an on‐target effect of ipatasertib. An open‐label, single‐arm, single‐sequence, signal‐seeking st...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley
2022-12-01
|
| coleção: | Clinical and Translational Science |
| Acesso em linha: | https://doi.org/10.1111/cts.13420 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|